Skip to main content

Table 1 Patients’ characteristics at baseline

From: The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial

 

All patients

N = 92

MTX+plac

n = 50

MTX+pred

n = 42

% female

59

56

62

Age

57 (47–65)

54 (46–65)

58 (47–67)

Smoking, as number of cigarettes per day

0 (0–5)

0 (0–0.5)

0 (0–5)

RF status, % positive

63

70

56

HAQ score, 0–3

1.1 (0.63–1.6)

1.2 (0.63–1.6)

1.1 (0.63–1.5)

General health VAS, 0–10

5.0 (2.7–6.7)

5.1 (3.6–6.6)

4.7 (2.2–6.7)

TJC28

10 (6–17)

9.5 (6–13)

12 (5–18)

SJC28

11 (7–15)

11 (7–15)

11 (6–15)

ESR mm/h

31 (19–44)

29 (19–43)

31 (18–45)

CRP mg/L

16 (2.7–41)

16 (5.5–42)

16 (1.9–37)

DAS28

5.6 (4.9–6.6)

5.6 (5–6.3)

5.6 (4.1–6.9)

MBDA score, 1–100

51 (39–71)

54 (40–72)

49 (40–70)

  1. No statistically significant differences in baseline characteristic between MTX+plac and MTX+pred groups. Values are median (interquartile range) or percentage
  2. RF, rheumatoid factor (RF status was available for 82 of 92, 43 of 50, and 39 of 42 patients, respectively); MTX, methotrexate; HAQ, health assessment questionnaire; VAS, visual analogue scale general health; TJC28, tender joint count assessing 28 joints; SJC28, swollen joint count assessing 28 joints; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28, 28-joint-based disease activity score; MBDA, multi-biomarker disease activity; higher scores of HAQ, VAS, and MBDA score reflect worse scores; MTX+plac, the methotrexate and placebo strategy; MTX+pred the methotrexate and prednisone strategy